Skip to main content
. 2022 Jul 18;12(12):5574–5595. doi: 10.7150/thno.70754

Figure 4.

Figure 4

Treatment with UroA and UAS03 reduce expression and activity of MRP2. A. Parental HCT-116 and HCT-116 FUR cells were used to evaluate MRP2 efflux of CDFDA. MRP2 transporter assay was performed using CDCFDA substrate and measured intracellular CDCFDA after incubation 1 h in the presence of Vehicle (0.1% DMSO) or UroA or UAS03 and 5FU (50 μM) B. Parental HCT-116 and HCT-116 FUR cells were treated with vehicle (0.1% DMSO) or UroA or UAS03 (50 µM) and 5FU (50 μM) for 24 h. Total RNA was isolated and mRNA levels of MRP2 were determined by real time PCR. C. HCT-116 -FUR cells were treated with UroA or UAS03 in the presence of 5 FU (50 µM) for 24 h. MRP2 protein levels were measured by Western blots and quantified fold change. D. Levels of 5FU measured in HCT-116 parental and HCT-116 5FUR cells. Cells in 96 well plate treated with vehicle (0.1% DMSO) or UroA or UAS03 (50 μM) for 24 h and followed by 90 min of 5FU (50 μM) treatment. Total 5FU extracted in to 10% methanol and levels of 5FU determined using HPLC as described in methods. Error bars indicate ±SEM. Statistics performed using unpaired t-test. ns: non-significant. *p < 0.05, **p < 0.01, ***p < 0.001.